Gan&Lee Pharmaceuticals Begins Phase I Dosing in GZC8072 Obesity and Diabetes Study

Stock News

Sep 07

Gan&Lee Pharmaceuticals (SH: 603087) has announced that its wholly-owned subsidiary, Gan&Lee Pharmaceuticals Shandong Co., Ltd., has successfully administered the first dose to a volunteer in a Phase I clinical trial for its novel drug candidate, GZC8072, which is being conducted in China.

GZC8072 is a next-generation, biased ultra-long-acting oral polypeptide weekly preparation. The therapy is being developed as a potential treatment for obesity, overweight, and type 2 diabetes. The company received the Drug Clinical Trial Approval Notices from the National Medical Products Administration for these two indications in August and September 2026, respectively.

The clinical development of this candidate is progressing as scheduled, with the first subject having now been dosed in the Phase I portion of the study. GZC8072 represents a significant milestone, as no GLP-1 oral weekly formulation has yet received market approval anywhere in the world. As of June 30, 2026, the company has invested a total of RMB 66.33 million in the GZC8072 project's research and development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/news/1131915744"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131915744\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131915744?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-07 15:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131915744","market":"hk","top_or_hot":-1,"title":"Gan&Lee Pharmaceuticals Begins Phase I Dosing in GZC8072 Obesity and Diabetes Study","media":"Stock News","content":"<p><b>Gan&Lee Pharmaceuticals</b> (SH: 603087) has announced that its wholly-owned subsidiary, Gan&Lee Pharmaceuticals Shandong Co., Ltd., has successfully administered the first dose to a volunteer in a Phase I clinical trial for its novel drug candidate, GZC8072, which is being conducted in China.<br><br>GZC8072 is a next-generation, biased ultra-long-acting oral polypeptide weekly preparation. The therapy is being developed as a potential treatment for obesity, overweight, and type 2 diabetes. The company received the <i>Drug Clinical Trial Approval Notices</i> from the National Medical Products Administration for these two indications in August and September 2026, respectively.<br><br>The clinical development of this candidate is progressing as scheduled, with the first subject having now been dosed in the Phase I portion of the study. GZC8072 represents a significant milestone, as no GLP-1 oral weekly formulation has yet received market approval anywhere in the world. As of June 30, 2026, the company has invested a total of RMB 66.33 million in the GZC8072 project's research and development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gan&Lee Pharmaceuticals Begins Phase I Dosing in GZC8072 Obesity and Diabetes Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGan&Lee Pharmaceuticals Begins Phase I Dosing in GZC8072 Obesity and Diabetes Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-07 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Gan&Lee Pharmaceuticals</b> (SH: 603087) has announced that its wholly-owned subsidiary, Gan&Lee Pharmaceuticals Shandong Co., Ltd., has successfully administered the first dose to a volunteer in a Phase I clinical trial for its novel drug candidate, GZC8072, which is being conducted in China.<br><br>GZC8072 is a next-generation, biased ultra-long-acting oral polypeptide weekly preparation. The therapy is being developed as a potential treatment for obesity, overweight, and type 2 diabetes. The company received the <i>Drug Clinical Trial Approval Notices</i> from the National Medical Products Administration for these two indications in August and September 2026, respectively.<br><br>The clinical development of this candidate is progressing as scheduled, with the first subject having now been dosed in the Phase I portion of the study. GZC8072 represents a significant milestone, as no GLP-1 oral weekly formulation has yet received market approval anywhere in the world. As of June 30, 2026, the company has invested a total of RMB 66.33 million in the GZC8072 project's research and development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1131915744","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131915744","pubTimestamp":1788767798,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Gan&Lee Pharmaceuticals (SH: 603087) has announced that its wholly-owned subsidiary, Gan&Lee Pharmaceuticals Shandong Co., Ltd., has successfully administered the first dose to a volunteer in a Phase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603087":"甘李药业","BK0239":"医药制造","MDTX":"Corgi MediaTek 2x Daily ETF","PSYK":"PSYK ETF","BMED":"iShares Health Innovation Active ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF"},"translate_title":"Gan&Lee Pharmaceuticals 开始 GZC8072 肥胖和糖尿病研究 I 期给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603087":1,"IBBJ":1,"BMED":1,"PSYK":1,"MDTX":1,"IBBQ":1},"content_text":"Gan&Lee Pharmaceuticals (SH: 603087) has announced that its wholly-owned subsidiary, Gan&Lee Pharmaceuticals Shandong Co., Ltd., has successfully administered the first dose to a volunteer in a Phase I clinical trial for its novel drug candidate, GZC8072, which is being conducted in China.GZC8072 is a next-generation, biased ultra-long-acting oral polypeptide weekly preparation. The therapy is being developed as a potential treatment for obesity, overweight, and type 2 diabetes. The company received the Drug Clinical Trial Approval Notices from the National Medical Products Administration for these two indications in August and September 2026, respectively.The clinical development of this candidate is progressing as scheduled, with the first subject having now been dosed in the Phase I portion of the study. GZC8072 represents a significant milestone, as no GLP-1 oral weekly formulation has yet received market approval anywhere in the world. As of June 30, 2026, the company has invested a total of RMB 66.33 million in the GZC8072 project's research and development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}